![]() ACIP recommends MenACWY booster doses for previously vaccinated persons who become or remain at increased risk. ACIP also recommends routine vaccination with MenACWY for persons aged ≥2 months at increased risk for meningococcal disease caused by serogroups A, C, W, or Y, including persons who have persistent complement component deficiencies persons receiving a complement inhibitor (e.g., eculizumab or ravulizumab ) persons who have anatomic or functional asplenia persons with human immunodeficiency virus infection microbiologists routinely exposed to isolates of Neisseria meningitidis persons identified to be at increased risk because of a meningococcal disease outbreak caused by serogroups A, C, W, or Y persons who travel to or live in areas in which meningococcal disease is hyperendemic or epidemic unvaccinated or incompletely vaccinated first-year college students living in residence halls and military recruits. These guidelines will be updated as needed on the basis of availability of new data or licensure of new meningococcal vaccines.ĪCIP recommends routine vaccination with a quadrivalent meningococcal conjugate vaccine (MenACWY) for adolescents aged 11 or 12 years, with a booster dose at age 16 years. ![]() This report also contains new recommendations for administration of booster doses of serogroup B meningococcal (MenB) vaccine for persons at increased risk for serogroup B meningococcal disease. ARTHUR BIRTHDAY V1 DOWNLOAD UPDATEAs a comprehensive summary and update of previously published recommendations, it replaces all previously published reports and policy notes. This report compiles and summarizes all recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |